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Abstract 
Background: HIV‑infected individuals on antiretroviral therapy (ART) require treatment with artemisinin‑based 
combination therapy (ACT) when infected with malaria. Dihydroartemisinin–piperaquine (DPQ) is recommended 
for treatment of Plasmodium falciparum malaria, but its efficacy and safety has not been evaluated in HIV‑infected 
individuals on ART, among whom drug–drug interactions are expected. Day‑42 adequate clinical and parasitological 
response (ACPR) and incidence of adverse events were assessed in HIV‑infected individuals on non‑nucleoside reverse 
transcriptase inhibitor‑based ART (efavirenz and nevirapine) with uncomplicated P. falciparum malaria treated with 
dihydroartemisinin–piperaquine.
Methods: An open label single arm clinical trial was conducted in Malawi (Blantyre and Chikhwawa districts) and 
Mozambique (Manhiça district) involving patients aged 15–65 years with uncomplicated P. falciparum malaria who 
were on efavirenz‑based or nevirapine‑based ART. They received a directly‑observed 3‑day standard treatment of 
DPQ and were followed up until day 63 for malaria infection and adverse events. Day‑42 PCR‑corrected‑ACPRs (95% 
confidence interval [CI]) were calculated for the intention‑to‑treat (ITT) population.
Results: The study enrolled 160 and 61 patients on efavirenz and nevirapine‑based ART, with a baseline geometric 
mean (95% CI) parasite density of 2681 (1964–3661) and 9819 (6606–14,593) parasites/µL, respectively. The day‑42 
PCR‑corrected ACPR (95% CI) was 99.4% (95.6–99.9%) in the efavirenz group and 100% in the nevirapine group. Seri‑
ous adverse events occurred in 5.0% (8/160) and 3.3% (2/61) of the participants in the efavirenz and nevirapine group, 
respectively, but none were definitively attributable to DPQ. Cases of prolonged QT interval (> 60 ms from baseline) 
occurred in 31.2% (48/154) and 13.3% (8/60) of the patients on the efavirenz and nevirapine ART groups, respectively. 
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Background
Malaria and human immunodeficiency virus (HIV) infec-
tions co-exist in most parts of sub-Saharan Africa [1]. 
Antiretroviral treatment (ART) naïve HIV-infected indi-
viduals are more susceptible to Plasmodium falciparum 
malaria infection than the HIV-uninfected population 
[2, 3]. The World Health Organization (WHO) recom-
mends the use of artemisinin-based combination therapy 
(ACT) to treat P. falciparum malaria infections [4]. Dihy-
droartemisinin–piperaquine (DPQ) is one of the most 
commonly used WHO-recommended ACT, but there 
are few data about its efficacy and safety in those taking 
ART despite the fact that large numbers of HIV-infected 
patients on ART are likely to be treated with DPQ for 
malaria.
Most ART regimens in sub-Saharan Africa contain 
non-nucleoside reverse transcriptase inhibitors, efavirenz 
and nevirapine. These drugs are metabolized by the 
cytochrome (CYP) P450 enzymes, particularly CYP3A4 
and CYP2B6, which also metabolize artemisinin-deriv-
atives and piperaquine [5–7]. Thus, co-administration 
of ART and DPQ may result in drug–drug interactions 
[5]. Indeed, a recent pharmacokinetic study found that 
in malaria uninfected HIV-infected individuals on efa-
virenz-based ART, piperaquine concentrations were 43% 
lower than ART naïve controls [8]. This drug–drug inter-
action may compromise DPQ’s efficacy. In addition, 
malaria uninfected HIV-infected individuals on nevirap-
ine-based ART treated with DPQ had higher piperaquine 
concentrations than ART naïve controls who received 
DPQ only [8]. This drug–drug interaction may increase 
piperaquine-related adverse events.
In view of the limited data on the efficacy and safety 
of DPQ in HIV-malaria co-infected patients, a single 
arm clinical trial was conducted to estimate the effi-
cacy of DPQ when used to treat parasitologically-con-
firmed uncomplicated clinical P. falciparum malaria in 
HIV-infected people on standard ART regimens (efa-
virenz- or nevirapine-based ART). Specifically, the trial 
assessed the day-42 PCR-corrected adequate clinical and 
parasitological response [ACPR] to examine whether it 
exceeds 90%, the WHO recommended benchmark for an 
efficacious anti-malarial drugs [9]. In addition, the trial 
assessed the safety of DPQ by determining the incidence 
of adverse events.
Methods
Study sites and study population
This study was part of a multi-country single arm clini-
cal trial aimed at assessing the efficacy and safety of two 
artemisinin-based combinations (DPQ and artemether–
lumefantrine) when used to treat malaria in HIV-infected 
adults on standard ART. One of the single arm trial 
assessing the efficacy and safety of AL was conducted 
in Zambia and findings have been reported elsewhere 
[10]. In this paper, findings from another single arm 
trial assessing the efficacy and safety of DPQ which was 
conducted from October 2013 to June 2015 at Queen 
Elizabeth Central Hospital and Chikhwawa District Hos-
pital in Malawi as well as Manhiça District Hospital in 
Mozambique, are reported. These are settings of moder-
ate-high transmission of malaria [11, 12] and high HIV 
prevalence [13, 14]. Blantyre is an urban district in South-
ern Malawi with an estimated population 1,239,647, 
while Chikhwawa is a rural district located 34 km south 
of Blantyre with an estimated population of 518,284. In 
2014, the malaria parasite prevalence in under-five chil-
dren in Malawi was 33% and higher in rural (37%) than 
urban areas (11%) [11]. HIV prevalence in Malawi was 
estimated at 10.6% in 2015 [13]. Manhiça is a rural dis-
trict in Southern Mozambique located 80  km north of 
Maputo city, with an estimated population of 178,000 in 
2014. Malaria parasite prevalence in under-five children 
was estimated at 51% in 2013 [12] while HIV prevalence 
in the district was estimated at 39.9% in 2010 [14].
During the study period, the criteria for initiating ART 
in the two countries were WHO HIV disease stages 3 or 
4, CD4 cell count < 350, pregnancy or lactation [15]. In 
October–December 2013, > 87% of ART individuals in 
Malawi were on a fixed dose combination of tenofovir/
These were not clinically significant and resolved spontaneously over time. As this study was not designed to com‑
pare the efficacy and safety of DPQ in the two ART groups, no formal statistical comparisons were made between the 
two ART groups.
Conclusions: DPQ was highly efficacious and safe for the treatment of malaria in HIV‑infected patients concurrently 
taking efavirenz‑ or nevirapine‑based ART, despite known pharmacokinetic interactions between dihydroartemisinin–
piperaquine and efavirenz‑ or nevirapine‑based ART regimens.
Trial registration Pan African Clinical Trials Registry (PACTR): PACTR201311000659400. Registered on 4 October 2013, 
https ://pactr .samrc .ac.za/Searc h.aspx
Keywords: Human immunodeficiency virus, Antiretroviral drugs, Dihydroartemisinin–piperaquine, Malaria, Drug–
drug interactions
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lamivudine/efavirenz while 6% were on stavudine/lami-
vudine/nevirapine or zidovudine/lamivudine/nevirapine 
[16]. In Mozambique, the majority of the ART individu-
als were on fixed dose zidovudine/lamivudine/nevirapine 
but the use of fixed dose tenofovir/lamivudine/efavirenz 
increased steadily over the study period. In both coun-
tries, artemether–lumefantrine was the first-line treat-
ment for uncomplicated malaria. DPQ was registered but 
not routinely available within the public health system in 
the two countries. Nevertheless, it was evaluated in this 
study because it is one of the WHO recommended arte-
misinin-based combinations and has a more convenient 
dosing schedule than AL (once daily for 3 days). The effi-
cacy and safety of AL was assessed in a separate trial [10].
Study design and clinical procedures
This was a single arm clinical trial (Registration number: 
PACTR201311000659400). HIV-infected patients on 
nevirapine- or efavirenz-based ART suspected of hav-
ing malaria were pre-screened through history taking 
and clinical examination to determine their eligibility for 
the study. The study inclusion criteria were as follows: 
age ≥ 15 to ≤ 65 years; weight ≥ 35 kg; documented fever 
(axillary ≥ 37.5  °C) or history of fever 24  h prior enrol-
ment; smear positive P. falciparum malaria monoinfec-
tion with asexual malaria parasite densities < 200,000/µL; 
ability to swallow oral medications and willingness and 
ability to comply with scheduled visits, supervised treat-
ment administration, laboratory tests, and other study 
procedures. The following were the exclusion criteria: 
severe malaria as per WHO criteria [17]; mixed infec-
tion with another Plasmodium species; haemoglobin 
(Hb) concentration < 7 g/dL; severe sickle cell disease or 
sickle-haemoglobin C anaemia; evidence of pregnancy or 
lactation; use of any anti-malarial treatment or drug with 
anti-malarial activity within the past 1 month, except cot-
rimoxazole; history of DPQ hypersensitivity reactions; 
gastrointestinal diseases that could alter gut absorption 
or motility; history of splenectomy; history of epilepsy 
or convulsions; pre-existing clinically-significant cardiac, 
liver, renal, neurological or psychiatric abnormalities; 
alternative clinical cause of fever other than malaria and 
participation in any investigational drug study in the past 
30 days.
Finger-prick blood samples were taken from those who 
satisfied the preliminary eligibility criteria and tested for 
malaria using Rapid Diagnostic Test (RDT) (SD BIO-
LINE Malaria Ag P.f/Pan test produced by Alere) and 
for haemoglobin concentration using Hemocue Hae-
moglobinometer. Thick blood smear microscopy exami-
nations were performed on patients with RDT positive 
malaria while clinical examinations were performed in 
those with confirmed malaria parasitaemia. Consenting 
participants were enrolled and scheduled for a 3-day hos-
pital admission.
The participants received dihydroartemisinin–pipe-
raquine  (Eurartesim®, Sigma Tau): 3 tablets for study 
participants < 60  kg or 4 tablets study for partici-
pants ≥ 60 kg. Each tablet contained dihydroartemisinin/
piperaquine 40  mg/320  mg, respectively, administered 
at 0 h, 24 (+ 4) and 48 (+ 4) h after the first dose. Par-
ticipants’ vital signs were measured at 6-hourly intervals 
and adverse events were monitored. A 12-Lead electro-
cardiogram (ECG) was performed before the first dose 
of DPQ and within 2 h after administration of the third 
dose DPQ. Any patient with Fridericia-corrected QT 
(QTcF) interval of ≥ 450  ms or QTc increase of > 60  ms 
from the baseline underwent follow-up ECGs until reso-
lution of the abnormality. Participants were discharged at 
least 24 h after taking the third (last) dose of DPQ (post-
treatment day 3) and advised to come for follow up vis-
its on post-treatment days 7 (± 1), 14 (± 1), 21 (± 2), 28 
(± 2), 35 (± 2), 42 (± 2) and 63 (± 2). Participants were 
encouraged to return to the health facility any time they 
felt unwell (unscheduled visits). All adverse events were 
graded using the DAIDS criteria [18]. Adverse events 
with onset or increased severity after the first dose of 
DPQ were counted as treatment-emergent adverse events 
(TEAEs). During follow up visits, participant’s time and 
any incurred expenses when attending the study clinic 
were appropriately compensated, as approved by the eth-
ics committees.
Laboratory procedures
During the admission period, thick blood slides were 
collected pre-dosing and at 6-hourly intervals until after 
obtaining two consecutive malaria negative smears. The 
slides were also collected at scheduled and unscheduled 
follow-up visits. The slides were Giemsa-stained and read 
by an experienced microscopist using standard proto-
cols [19]. For quality control, all slides were re-read by 
a second microscopist; a third microscopist settled any 
discrepant readings. Dry blood spot (DBS) samples were 
collected on filter paper (Whatman  3MM®) at baseline 
and during recurrent malaria episodes. Parasite DNA 
was extracted from the DBS samples, amplified using 
polymerase chain reaction (PCR) and genotyped for 
merozoite specific protein (MSP) 1 and 2 to distinguish 
malaria recrudescence from re-infection, using methods 
previously described [20]. Samples that did not produce 
results were classified as indeterminate.
Venous blood samples were collected on days 0, 3, 28, 
42 and 63 for biochemistry tests using a Beckman  CX5® 
Chemistry analyzer, on days 0, 3, 7, 28, 42 and 63 for 
haematological tests using a Beckman  Coulter® HMX 
Analyzer and on days 0, 28, and 63 for CD4 cell count 
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measurement using a BD FACSCount™ machine. Plasma 
samples collected on days 0, 28, and 63 were stored for 
future HIV viral load assays.
Blood samples for sparse pharmacokinetic (PK) assays 
were collected in sampling windows of 0–6, 6–48, 
48–60 h, and on days 7, 21, 28 or 35 from first dose, as 
previously recommended [21]. In this paper, the rela-
tionship between day-7 concentrations and ACPR was 
explored since day-7 concentrations of the slowly elimi-
nated partner drug of ACT have been shown to be a bet-
ter determinant of therapeutic response than the area 
under the concentration–time curve [22]. The PK sam-
ples were analysed using a previously described HPLC–
UV assay method [8]. The lower limit of quantitation 
(LLOQ) of the piperaquine was 25  ng/mL, with a coef-
ficient of variation of < 10%. The PK laboratory at the 
Malawi-Liverpool Wellcome Trust Clinical Research Pro-
gramme in Blantyre, Malawi, participated in the World 
Wide Antimalarial Resistance Network’s external quality 
assurance programme [23].
Study endpoints
The primary study endpoint was proportion of patients 
with PCR-corrected day 42 ACPR, defined as patients 
who did not have parasitaemia on day 42 that exhibited 
identical P. falciparum malaria PCR markers (merozoite 
surface protein 1 and 2) with those at baseline, irrespec-
tive of axillary temperature, and who had not previously 
met any of the criteria of early treatment failure (ETF), 
late clinical failure (LCF) or late parasitological failure 
(LPF). Standard WHO definitions of ETF and LCF were 
used [9].
The other primary study end points were grade 3 or 4 
TEAEs of special interest (Fridericia-corrected QT inter-
val prolongation, dizziness, palpitations, urticaria or itch-
iness) and serious adverse events (SAEs) as per standard 
definitions [24]. Local study physicians determined the 
relationships between DPQ and the adverse events (AEs). 
A Data Safety and Monitoring Board reviewed serious 
AEs and adverse events of special interest (AESIs) and 
assessed the validity of study physicians’ decisions. Sec-
ondary endpoints, included day 42 PCR-uncorrected 
ACPR, time for parasite to decline by 50%  (PC50) and 
90%  (PC90), fever clearance time and trends in haemoglo-
bin concentrations and CD4 cell counts from baseline to 
day 28.
Samples size
Sample size calculation was based on estimates of total 
treatment failure rate (TTFR). The estimated day-42 
PCR corrected TTFR was ≤ 10% [25]. A precision of 
5%, around this point estimate, allowed the upper limit 
of the 95% Wald binomial confidence interval to be 15%. 
Using the formula for estimating a single study popula-
tion sample size [26], our effective sample size was esti-
mated at 138 for each ART type. The final sample size, 
for each ART group, was 163 after adjusting for an antici-
pated loss-to-follow-up rate of 15%. This sample size 
was achieved for the efavirenz-ART group but not for 
nevirapine-ART group, as the ART programs in both 
countries had successfully transitioned from nevirapine- 
to efavirenz-based ART first-line regimens. Sample size 
calculations including all subsequent statistical analysis 
were performed in STATA 13.1
Statistical analyses
For the primary end-point, three analysis populations 
were used. Firstly, the Intention-to-treat (ITT) popu-
lation included patients who received at least 1 dose of 
study medication. Secondly, the per-protocol (PP) pop-
ulation included all participants who had the primary 
endpoint data at day 42, received a full course of DPQ 
and adhered to the follow-up visit schedule. Thirdly, the 
safety population included all patients who received any 
amount of study medication and had at least 1 assess-
ment after dosing. ACPR plus 95% CI in PP and ITT 
populations were calculated. Sensitivity analyses were 
performed using the ITT and PP populations that first 
considered all participants with missing data as having 
parasitological failure and then considered the same par-
ticipants as having treatment success.
Statistical analyses for secondary ACPR endpoints 
were similar to the primary endpoints. In addition, the 
Kaplan–Meier survival plots were used to summarize the 
time to PCR-corrected and uncorrected treatment fail-
ure. Parameters assessing post-treatment parasite clear-
ance  (PC50,  PC90 and parasite clearance half-life) in the 
two ART groups were estimated using the WorldWide 
Antimalarial Resistance Network parasite clearance esti-
mator, as described elsewhere [27].
Descriptive statistics were computed for baseline vari-
ables in the two ART groups. However, as this study was 
designed to estimate and not to compare efficacy and 
safety of DPQ between the two ART groups, no formal 
statistical comparisons of baseline characteristics effi-
cacy or safety endpoints were made between the two 
ART groups. As part of a priori exploratory analysis, and 
where appropriate, Wilcoxon rank-sum/Mann–Whitney 
U test was used to compare distributions of the day-7 
piperaquine concentrations in those who attained or did 
not attain ACPR by day 42. Piperaquine concentrations 
below the LLOQ were imputed to half the lower limit of 
quantification and included in the estimation of median 
piperaquine exposure if the imputed values were < 10% 
of the data. Additionally, Wilcoxon matched paired 
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signed-rank test was used to compare baseline and day 
28 CD4 cell and haemoglobin values in each ART group.
Results
Study profile
A total of 1864 patients presenting at the health facili-
ties with symptoms suggestive of malaria were screened 
for trial eligibility (Fig. 1). Two hundred and twenty-one 
patients with positive P. falciparum malaria blood met 
the eligibility criteria and were enrolled in the trial. None 
of the participants on nevirapine-ART and 5.6% (9/160) 
on efavirenz-ART were lost-to-follow-up or withdrew 
consent.
Baseline characteristics
The baseline characteristics of enrolled study par-
ticipants are summarized in Table  1. Most of the 
participants in the nevirapine-ART group (83.6%, 
N = 61) were from Mozambique while those on efa-
virenz-ART were predominantly from Malawi (75%, 
N = 160). Participants in the nevirapine-ART group 
were older and had been on ART for a longer period 
than those in the efavirenz-ART group. The geomet-
ric mean parasite density and median CD4 cell count 
were higher in the nevirapine-ART group than in the 
efavirenz-ART arm. A lower proportion of participants 
on nevirapine-ART were on cotrimoxazole prophylaxis 
compared with those on efavirenz-ART. There were no 
major differences between the two groups in body mass 
index and hemoglobin concentrations. The median 
Fridericia-corrected QT (QTcF) interval at recruitment 
was longer in the nevirapine-ART group than the efa-
virenz-ART group.
Fig. 1 Trial profile and flow chart of participants. Trial profile and flow chart of participants enrolled into the efavirenz (EFV) and nevirapine (NVP) 
antiretroviral groups in Malawi and Mozambique and receiving dihydroartemisinin–piperaquine (DPQ)
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Treatment dosage and tolerability
The total median (range) dosages of dihydroarte-
misinin and piperaquine administered to participants 
were 7.0  mg/kg (5.1–9.9) and 56.3  mg/kg (40.9–79.1), 
respectively in the efavirenz-ART group and 7.0  mg/
kg (5.6–8.6) and 55.7  mg/kg (45.0–68.6), respectively in 
the nevirapine-ART group. The dosages were well toler-
ated: 3 participants in the efavirenz-ART group and none 
in the nevirapine-ART group vomited following intake 
of DPQ. Participants who vomited were re-dosed and 
none was withdrawn from the study due to persistent 
vomiting.
Treatment efficacy
As shown in Table  2, only one participant in the efa-
virenz-ART group, with baseline CD4 count of 26 cells/
μL, had ETF on treatment day 2. Also, seven cases in 
the efavirenz-ART group had LPF. Parasite genotyp-
ing results were available in 6 of the 7 LPF cases which 
were all classified as re-infections. No treatment failures 
occurred in the nevirapine-ART group.
In the ITT analyses, the PCR-corrected day 42 ACPR 
was 99.4% (95% confidence interval [CI] 95.6–99.9%) 
in the efavirenz-ART group and 100% in the nevirap-
ine-ART group (see Additional file 1). The day 42 PCR-
uncorrected ACPR was 95.6% (95% CI 90.3–97.5%) in the 
efavirenz-ART group and 100% in the nevirapine-ART 
group (see Additional file 2).
In the PP analyses, the day 42 PCR-corrected ACPR 
was 99.3% (95% CI 95.4–99.9%) in the efavirenz-ART 
group and 100% in the nevirapine-ART group. The day 42 
PCR-uncorrected ACPR was 94.7% (95% CI 89.7–97.3%) 
in the efavirenz-ART group and 100% in the nevirapine-
ART group.
In sensitivity analyses which considered missed visits 
or samples, unavailable PCR results and loss to follow up 
as treatment failures, the day-42 PCR-corrected ACPR 
was 93.1% (95% CI 88.0–96.2%) in the ITT population 
and 98.8% (95% CI 95.1–99.7%) in the PP population. 
Details of the different scenarios accounting for the miss-
ing results are shown in Table 2.
Parasite clearance time
Parasite clearance parameters were calculated in 46 and 
84 participants in the nevirapine-and efavirenz-ART 
groups, respectively, who had detectable parasitemia at 






Age in years, median (IQR) 38.6 (32.3–44.7) 47.0 (37.9–51.8)
Female, % 107 (66.9) 46 (75.4)
Body mass index, kg/m2, median (IQR) 20.8 (19.3–22.7) 21.1 (18.5–23.9)
WHO BMI classification, n (%)
 Underweight 26 (16.3) 15 (24.6)
 Normal 123 (76.8) 35 (57.4)
 Overweight 5 (3.1) 6 (9.8)
 Obese 6 (3.8) 5 (8.2)
Duration on ART in months, median (IQR) 11 (5–32) 55 (33–70)
Presenting symptoms, n (%)
 Fever 146 (91.3) 57 (93.4)
 Headache 144 (90.0) 57 (93.4)
 Body aches 89 (55.6) 41 (67.2)
 Nausea 40 (25.0) 33 (54.1)
Axillary temperature at enrolment, median (IQR) 37.7 (37.0–37.9) 37.1 (36.6–37.8)
Geometric Mean Parasite density, 95% CI. 2681 (1964–3661) 9819 (6606–14,593)
 Parasite density > 2000 parasites/µL, n (%) 84 (52.5) 53 (86.9)
Pre‑treatment hemoglobin concentration, g/dL, median (IQR) 12.2 (10.9–13.5) 11.9 (10.7–12.7)
Pre‑treatment CD4 cell count, median (IQR) cells/mm3 256 (140–360) 390 (237–500)
 CD4 cell count < 350, n (%) 106 (66.3) 27 (44.3)
Median (IQR) QTcF interval (ms) 395 (360–418) 418 (389–438)
Reported use of any insecticide‑treated bed net before presentation, % (n) 44 (27.5) 16 (26.2)
Current use of cotrimoxazole prophylaxis, % (n) 109 (68.1) 12 (19.6)
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two or more post-dosing time points. The median (range) 
 PC50 and the median (range)  PC90 in the ITT population 
were 3.1 (0.2–10.3)  h and 8.2 (2.4–19.7)  h, respectively, 
in the nevirapine-group and 4.2 (0.6–40.3)  h and 10.1 
(3.2–63.1)  h, respectively, in the efavirenz-group. The 
median parasite clearance half-life (range) were 2.1 (1.1–
6.8) and 2.2 (1.2–9.8) h in the nevirapine- and efavirenz-
ART groups, respectively (Fig. 2). One participant (2.2% 
[95% CI 0.3–14.8]) in the nevirapine-ART group and 
five participants (6.0% [2.5–13.7]) in the efavirenz-ART 
group, had parasite clearance half-life of > 5.5  h. All six 
participants had a baseline parasite density of > 3500 par-
asites/µL and CD4 cell count of < 250 cells/mm3. None 
of these six participants experienced malaria recurrence 
during the follow up period.
Day‑7 plasma piperaquine concentrations
On day 7 of follow-up, blood samples for plasma pipe-
raquine quantification were available from 179 of the 
retained 216 participants. Of these, 62.0% (111/179) had 
day-7 piperaquine concentrations that were below the 
LLOQ (< 25 ng/mL): 60.0% (81/135) in the efavirenz-ART 
Table 2 Efficacy outcomes and  adequate clinical and  parasitilogical response rates by  day 42 among  the  enrolled 
participants stratified by group of antiretroviral therapy
a Scenario 1: Indeterminate or unavailable PCR samples or loss to follow up by day 42 (n = 9, in efavirenz-ART group) in intention-to-treat population treated as 
treatment success
b Scenario 2: Indeterminate or unavailable PCR samples or loss to follow up by day 42 (n = 9, in efavirenz-ART group) in the intention-to-treat population treated as 
treatment failures
c Scenario 3: On cotrimoxazole prophylaxis in the intention-to treat analysis and combined with scenario 2 above
d Scenario 4: Not on cotrimoxazole prophylaxis in the intention-to treat and combined with scenario 2 above
e Scenario 5: Indeterminate or unavailable PCR samples in per-protocol population treated as treatment success
f Scenario 6: Indeterminate or unavailable PCR samples in per-protocol population treated as treatment failure




Early treatment failure‑no. (%) 1 (0.6) 0
 Development of danger signs or severe malaria 0 0
 Parasitaemia on day 2 greater than day 0 0 0
 Parasitemia on day 3 ≥ 25% of count on day 0 1 (0.6) 0
 Parasitemia on day 3 with axillary temperature ≥ 37.5 °C 0 0
Late clinical failure‑no. (%) 0 0
Late parasitological failure‑no. (%) 7 (4.4) 0
 Recrudescence 0 0
 Reinfection 6 (3.8) 0
 Indeterminate or sample unavailable 1 (0.6) 0
Adequate clinical and parasitolocal response rates by different scenarios
 Intention‑to‑treat analysis
  PCR‑corrected cure rate‑% (95% CI)
   Scenario  1a 99.4 (95.6–99.9) 100
   Scenario  2b 93.1 (88.0–96.2) 100
  PCR‑uncorrected cure rate‑% (95% CI)
   Scenario  1a 95.6 (90.3–97.5) 100
   Scenario  2b 89.4 (83.5–93.3) 100
   Scenario  3c 89.9 (82.3–94.4) 100
   Scenario  4d 89.8 (77.4–95.8) 100
 Per‑protocol analysis
  Number of patients 151 61
  PCR‑corrected cure rate‑% (95% CI)
   Scenario  5e 99.3 (95.4–99.9) 100
   Scenario  6f 98.8 (95.1–99.7) 100
  PCR‑uncorrected cure rate‑% (95% CI)
   Scenario  5e 95.3 (90.5–97.8) 100
   Scenario  6f 94.7 (89.7–97.3) 100
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group and 68.2% (30/44) in the nevirapine-ART group. 
The piperaquine values for these individuals were 
imputed to half the lower limit of quantification. How-
ever, since these values were more than > 10% of the 
data, they were excluded in calculation of median pipe-
raquine exposure. Overall, the median (range) day-7 
piperaquine concentration in participants with concen-
trations > LLOQ was 57 (25.5–592.8) ng/mL in the efa-
virenz-ART group and 79.1 (25.4–211.1) ng/mL in the 
nevirapine-ART group. After excluding < LLOQ values, 
participants who experienced malaria recurrence by day 
42 (n = 3) had a median (range) day-7 piperaquine con-
centration of 63.9 (49.7–78.9) ng/mL and this value was 
66.7 (25.4–592.8) ng/mL in participants who did not 
experience malaria recurrence (n = 65, p = 0.965).
Fever clearance
At baseline, 58.1% (93/160) of participants in the efa-
virenz-ART group and 31.1%, (19/61) in the nevirapine-
ART group were febrile (axillary temperature ≥ 37.5 °C). 
The median fever clearance time (IQR) was 6  h (6–60) 
in the efavirenz-ART group and 6 h (6–12) in the nevi-
rapine-ART group. By treatment day 2, only 3.8% (6/160) 
participants in the efavirenz-ART group and 1.6% (1/61) 
in the nevirapine-ART group were febrile.
Safety
From enrolment to follow-up day 63, there were 69 
adverse events of special interest (AESIs) (54 and 15 in 
the efavirenz-ART group and nevirapine-ART group, 
respectively) and 12 serious adverse events (SAEs) 
(10 and 2 in the efavirenz-ART group and nevirapine-
ART group, respectively) (Table  3). None of the SAEs 
and AESIs were judged to be definitely related to DPQ. 
Forty-eight (30.0%) of the AESIs in the efavirenz-ART 
group and 8 (13.1%) in the nevirapine-ART group were 
judged to be probably related to DPQ (Table  3). These 
were mostly cases of prolonged QTcF interval. One death 
occurred on day 59 in a participant on efavirenz-ART 
who had been treated for deep vein thrombosis from 
day 33 and had CD4 count persistently below 50 since 
enrolment. Additional file 3 provides details on the SAEs 
that occurred during follow up. Except for the death, all 
participants with AESIs and SAEs recovered without 
sequelae.
Haematological parameters
The mean (SD) haemoglobin concentration decreased 
from baseline to day 7 (efavirenz-ART group: 12.2 to 
11.7  g/dL, p < 0.001 and nevirapine-ART group: 11.7 to 
10.7  g/dL, p < 0.001), but increased thereafter up to day 
42, from 11.7 to 12.4  g/dL in the efavirenz-ART group 
(p < 0.001) and from 10.7 to 11.6 g/dL in the nevirapine-
ART group (p < 0.001). Following DPQ treatment, the 
median (IQR) CD4 cell count increased from baseline to 
day 28, from 257 (140–357) to 320 (216–521) in the efa-
virenz-ART group (p < 0.001) and from 390 (204–500) to 
429 (204–580) in the nevirapine-ART group (p = 0.133).
QT interval abnormalities
Data on baseline QTcF interval were available for 218 
participants; 158 and 60 in the efavirenz-ART and nevi-
rapine-ART group, respectively. The proportions of par-
ticipants with predose QTcF ≥ 450 ms were 3.8% (6/158) 
in the efavirenz-ART group and 11.7% (7/60) in the nev-
irapine-ART group. Only 4 participants in the efavirenz-
ART group had missing QTcF values on day 2 (last day 
of treatment). A change in QTcF interval of > 60 ms from 
baseline to day 2 occurred in 31.2% (48/154) and 13.3% 
(8/60) in the efavirenz and nevirapine groups, respec-
tively (Table  4). No participant had an absolute day 2 
QTcF interval ≥ 500 ms. Observed QTcF interval abnor-
malities resolved by day 7 or 14 of follow up. No cardio-
vascular abnormalities were detected in these individuals.
Discussion
The WHO recommends the use of first-line anti-malarial 
drugs with PCR-corrected ACPR of > 90%. In this study, 
the day 42 PCR-corrected ACPR for DPQ exceeded 99% 
among adult HIV-infected patients with uncomplicated 
malaria concurrently taking efavirenz- or nevirapine-
based ART; the lower limit of the 95% CI for the DPQ 
ACPR exceeded 95%. Rapid parasite clearance, similar to 
that in HIV-uninfected individuals [28–31] was achieved, 
Fig. 2 Parasite clearance half‑life. Parasite clearance half‑life in the 
intention‑to‑treat population stratified by antiretroviral therapy group 
[efavirenz (diamond) and nevirapine (circle)]. Red dotted middle line 
is the median parasite clearance rate, lower and upper red solid bars 
represent the interquartile range
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irrespective of the type of ART taken by the study par-
ticipants. Malaria reinfections occurred in the efavirenz-
ART group but, overall, day 42-PCR uncorrected ACPR 
remained high in both ART groups, suggesting that DPQ 
had a good prophylactic effect against malaria reinfec-
tions. DPQ treatment also resulted in rapid resolution of 
Table 3 Summary of serious adverse events and adverse events of special interest stratified by antiretroviral group
a n The number of participants that experienced the event; % is percentage of participants experiencing that event in the intention-to-treat population
b # The total number of events that occurred
c Fridericia corrected QT prolongation defined as change in QTc interval of > 60 ms from baseline to day 2 (last day) of antimalarial treatment, also reported separately 
(in detail) in Table 4






na (%) [#]b na (%) [#]b
Serious adverse events (SAEs) 8 (5.0), [10] 2 (3.3), [2]
Adverse event(s) of special interest (AESI) 54 (33.8), [54] 15 (24.6), [15]
 Fridericia corrected QT  prolongationc 48 (30.0) 8 (13.1)
 Palpitations 4 (2.5) 2 (3.3)
 Dizziness 2 (1.3) 2 (3.3)
 Urticaria 0 1 (1.6)
 Itchiness 0 1 (1.6)
 Chest pain 0 1 (1.6)
Drug‑related adverse events (SAEs)
 Not related 7 (4.4), [9] 2 (3.3), [2]
 Possibly related 1 (0.6), [1] 0
 Probably related 0 0
 Definitely related 0 0
Drug‑related adverse events (AESI)
 Not related 1 (0.6), [1] 4 (6.6) [4]
 Possibly related 5 (3.1), [5] 3 (4.9), [3]
 Probably related 48 (30.0), [48] 8 (13.1), [8]
 Definitely related 0 0
Table 4 Median Fridericia corrected QT interval (QTcF), and proportion with abnormal ECG findings from baseline to last 
day of dosing among participants in the efavirenz- (N = 158) and nevirapine- (N = 60) based antiretroviral therapy groups
IQR interquartile range, ECG electrocardiogram, ART antiretroviral drug, NA not applicable
a Adverse event of special interest
b N = 154 in Efavirenz group and 60 in the Nevirapine group
Time of ECG test Median (IQR) QTcF in ms Proportion with QTcF ≥ 450 ms Proportion with QTcF 
change > 60 ms from baseline 















NA NA n (%) n (%) n (%) n (%)
Day 0 395 (360–418) 418 (390–438) 6 (3.8) 7 (11.8) NA NA
Day 1 403 (383–423) 418 (388–437) 10 (6.3) 6 (10.0) 19 (12.3) 1 (1.7)
Day 2 424 (408–442) 434 (414–459) 29 (18.4) 21 (35.0) 48 (31.2) 8 (13.3)
Follow up visit after day 2 
(day 7 or 14 of follow up)
410 (384–436) 424 (402–437) 0 0 NA NA
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fever and marked improvement in haemoglobin concen-
trations irrespective of ART as well as improvement in 
CD4 cell count, especially in those taking efavirenz-based 
ART.
An anti-malarial treatment response depends on host 
immunity and anti-malarial drug blood concentrations. 
Efavirenz has been associated with induction of CYP3A4 
and CYP2B6 enzymes while nevirapine has been asso-
ciated with inhibition or sometimes induction of the 
enzymes [5]. Previous pharmacokinetic studies found 
that, compared with antiretroviral naïve HIV-infected 
individuals, those taking DPQ plus efavirenz-ART had 
lower piperaquine area under the concentration–time 
curve (AUC) [8, 32] while those taking DPQ plus nevi-
rapine-ART had higher piperaquine AUC [8]. Similarly, 
other studies found that when co-administered with efa-
virenz or nevirapine, ACT resulted in altered pharma-
cokinetics of artemisinin and its metabolites [33–37]. The 
finding of high efficacy of DPQ suggests that any altera-
tions in the pharmacokinetics of dihydroartemisinin 
or piperaquine due to efavirenz or nevirapine had lim-
ited clinical significance in this study population. How-
ever, this needs further confirmation in future studies 
which would correlate PK data with observed efficacy 
endpoints.
To date, no previous study has assessed the efficacy and 
safety of DPQ in malaria-HIV coinfected non-pregnant 
adults on ART. A previous Tanzanian study [38] found 
that HIV-infected adults with uncomplicated malaria on 
efavirenz-ART who were treated with artemether–lume-
fantrine had a lower PCR-uncorrected day 28 ACPR 
(82.5%) than HIV-infected antiretroviral naïve individu-
als (94.5%), while those on nevirapine-based ART had a 
higher day 28 PCR-uncorrected ACPR (97.6%). No cases 
of ETF were detected in a study population in which 
almost half of the participants had CD4 cell counts < 350. 
Thus, the study showed high efficacy of artemether and 
its metabolites (responsible for the initial clearance of 
malaria parasite [39, 40]) despite ART co-administration, 
which is consistent with our study findings. However, in 
contrast to our findings, the Tanzanian study found high 
rates of recurrent malaria in those on efavirenz-ART. 
This is likely to reflect the longer half life and hence supe-
rior prophylactic effect of the ACT-partner drug, pipe-
raquine, in this study compared with lumefantrine in the 
previous study.
Day-7 plasma ACT concentrations have been proposed 
as a marker of overall exposure of the longer acting part-
ner drug of ACT and have been shown to be predictive of 
treatment efficacy by day 28 after malaria treatment [22]. 
In the present malaria-HIV co-infected sub-population, 
most participants had day-7 piperaquine concentrations 
that were below the LLOQ. However, in participants 
who had piperaquine concentration values > LLOQ, the 
piperaquine concentrations were not significantly differ-
ent between those who experienced malaria recurrence 
by day 42 and those who did not. The observed < LLOQ 
concentrations could be due to increased metabolism 
of piperaquine, as a result of efavirenz induction of 
CYP3A4 enzymes, or a limitation in the HPLC assay to 
detect smaller concentrations of piperaquine. Neverthe-
less, the observed high efficacy of DPQ highlights that 
any PK interaction between efavirenz or nevirapine and 
piperaquine did not predict the clinical outcomes in this 
study.
Delayed parasite clearance (parasite clearance half-life 
of > 5.5  h) has been shown to be associated with resist-
ance of the parasites to artemisinins [41]. Although a 
smaller proportion of participants in both ART groups 
had parasite clearance half-life of > 5.5  h, they did not 
experience malaria recurrence in the follow up period, 
despite having most participants with piperaquine con-
centrations below the lower limit of quantification. Nota-
bly, they all had a low baseline CD4 cell count with a 
relatively higher malaria parasite load compared to the 
rest of the participants. This higher parasite load cou-
pled with low immunity at presentation could explain the 
delayed clearance of malaria parasites that was observed 
in these participants.
Treatment-emergent AESIs occurred in nearly a third 
and one-quarter of the participants on efavirenz- and 
nevirapine-based ART, respectively. However, only a 
few cases of AESIs in the efavirenz-group and none in 
the nevirapine-group were judged to be possibly associ-
ated with DPQ (Table  3). QTcF prolongation of at least 
60 ms from baseline to the last treatment day did occur 
in a sizable proportion of participants but none had an 
absolute QTcF interval of 500 ms and there were no clini-
cally detectable events. The QTcF prolongation resolved 
spontaneously by day 14. The observed QTcF prolonga-
tion may have been due to fever resolution [42, 43] rather 
than piperaquine, but whatever the mechanism, we can 
conclude that DPQ can be safely used in this group of 
patients. This observation is also in line with WHO’s rec-
ommendation that there is no evidence of increased risk 
of cardiotoxicity following exposure to current doses of 
DPQ for treatment of uncomplicated malaria [44]. Addi-
tionally, a similar phenomenon, of prolonged QTc inter-
val which resolves following recovery from malaria, has 
been previously observed in 17.1% (n = 152) of adults 
living with HIV and on efavirenz-based ART who were 
treated for uncomplicated malaria with artemether–
lumefantrine in Zambia [10]. Nevertheless, this needs 
to be confirmed in future studies of DPQ use in malaria-
HIV coinfected adults on efavirenz- or nevirapine based 
ART.
Page 11 of 13Sevene et al. Malar J          (2019) 18:277 
The major strengths of this study were the directly-
supervised DPQ dosing, large sample size of participants 
on efavirenz-based ART and minimal loss to follow-
up (< 5%). However, the required sample size was not 
achieved in the nevirapine-based ART group because the 
national ART programme phased out this regimen dur-
ing the course of the study. Nevertheless, participants in 
this group had high baseline parasite densities which per-
mitted accurate assessment of DPQ’s parasite clearance 
and prophylactic efficacy.
Nearly one-half of enrolled study participants in the 
efavirenz group had parasite densities of < 2000/mm3 and 
nearly two-thirds were on cotrimoxazole prophylaxis 
which has some antimalarial effects [45, 46]. Thus, it can 
be argued that the high ACPR found in the efavirenz-
group could have partly been due to the anti-malarial 
effects of cotrimoxazole and immunity-mediated clear-
ance of low density parasitaemias. However, day-42 PCR-
corrected and uncorrected ACPR did not significantly 
vary according to the use of cotrimoxazole prophylaxis or 
baseline parasite density. In addition, at least two-thirds 
of participants in this group had CD4 cell count < 350/
mm3 which is likely to have compromised their ability to 
clear parasites and prevent reinfections [2, 3, 25]. In spite 
of this, DPQ achieved high ACPR in this group suggest-
ing its high therapeutic and prophylactic effectiveness.
In this study, the day-42 PCR corrected and uncor-
rected ACPR appeared to be higher among individuals 
on nevirapine-based ART than among those on efa-
virenz-based ART. However, this study was not designed 
to compare the efficacy and safety of DPQ between the 
two groups and the full sample size was not achieved in 
the nevirapine arm. It is therefore inappropriate to make 
direct comparison of DPQ efficacy between individuals 
taking the two ART regimens.
Conclusion
This study found that dihydroartemisinin–piperaquine 
was highly efficacious and safe when used to treat 
uncomplicated P. falciparum malaria in individuals tak-
ing efavirenz or nevirapine-based ART. A higher than 
expected observed cases of QTc interval prolongation 
(> 60  ms from baseline to day 2) following treatment 
with dihydroartemisinin–piperaquine were observed and 
thought to likely be due to resolution of fever as part of 
the malaria recovery process. Under the “HIV Test and 
Treat” approach, many HIV-infected individuals in high 
burden countries will initiate ART early before they are 
severely immunosuppressed and this study supports the 
use of dihydroartemisinin–piperaquine for the treatment 
of uncomplicated malaria in such patients.
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Additional file 1. Day 42 PCR‑corrected efficacy plot. Kaplan–Meier 
survival plot of participants who were treated with dihydroartemisinin–
piperaquine (DHA PPQ) in the efavirenz (EFV)‑ and nevirapine (NVP) based 
antiretroviral therapy (ART) groups according to polymerase chain reac‑
tion (PCR) corrected adequate clinical and parasitological response (ACPR) 
by day 42 in the intention‑to‑treat population with loss to follow up and 
indeterminate or unavailable PCR samples treated as treatment success.
Additional file 2. Day 42 PCR‑uncorrected efficacy plot. Kaplan–Meier 
survival plot of participants who were treated with dihydroartemisinin–
piperaquine (DHA PPQ) in the efavirenz (EFV)‑ and nevirapine (NVP) 
based antiretroviral therapy (ART) groups according to polymerase chain 
reaction (PCR) uncorrected adequate clinical and parasitological response 
(ACPR) by day 42 in the intention‑to‑treat population with loss to follow 
up and indeterminate or unavailable PCR samples treated as treatment 
success.
Additional file 3. Details of serious adverse events that occurred during 
follow up.
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